Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

REFERENCES

• Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: The birth of “me-too” HIV-1 integrase inhibitors. Retro virology. 2009;6:25.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Section accessed October 18,2012 [F-4, Table 5a].
   Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359(4):355–365.
   PubMed Web of Science ®Google Scholar
• Mbisa JL, Martin SA, Cane PA. Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist. 2011;4:65–76.
   PubMedGoogle Scholar
• DeJesus E, Cohen C, Elion R, et al. First report of raltegra-vir (RAL, MK-0518) use after virologic rebound on elvite-gravir (EVT, GS 9137). Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22–25, 2007; Sydney, Australia. Abstract TUPEB032.
   Google Scholar
• Kawasuji T, Johns BA, Yoshida H, et al. Carbamoyl pyri-done HIV-1 integrase inhibitors. 2. Bi- and tricyclic deriva-tives result in superior antiviral and pharmacokinetic pro-files. J Med Chem. 2013;56(3):1124–1135.
   PubMed Web of Science ®Google Scholar
• Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegra-vir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012 ;61(3):297–301.
   PubMed Web of Science ®Google Scholar
• Min S, DeJesus E, McCurdy L, et al. Pharmacokinetics (pK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/G5K1265744, a next generation once daily HIV integrase inhibitor [poster]. Pre-sented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco, CA.
   Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiret-roviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011 ;55(2):813–821.
   PubMed Web of Science ®Google Scholar
• Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS One. 2012;7(1):e28238.
   PubMed Web of Science ®Google Scholar
• Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral charac-teristics of S/G5K1265744, an HIV integrase inhibitor (INI) dosed by oral or long-acting parenteral injection [slides]. Presented at: 52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9–12, 2012; San Francisco, CA.
   Google Scholar
• National Institutes of Allergy and Infectious Diseases, Divi-sion of Acquired Immunodeficiency Syndrome. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://rsc.tech-res.com/Document/safe-tyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed April 6, 2012.
   Google Scholar
• Hazuda DJ, Miller MD, Nguyen BY, Zhao J, for the P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase ll study in patients with triple-class resistant HIV-1 infection [abstract 8]. Antivir Ther. 2007;12:S10.
   Web of Science ®Google Scholar
• McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a Phase ll study of elvitegravir (GS-9137) [abstract 9]. Antivir Ther. 2007;12:S11.
   Google Scholar
• Malet I, Wirden M, Fourati S, et al. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. 2011 ;66(7):1481–1483.
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Che-mother. 2010;54(1):254–258.
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737–1745.
   PubMed Web of Science ®Google Scholar
• Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings. HIV/AIDS (Auckl). 2011;3:35–44.
   PubMedGoogle Scholar
• Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol. 2010;6(1):95–103.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Noble S. Efavirenz. Drugs. 1998;56: 1055-1064; discussion 1065–1066.
   Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 inte-grase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43(1):1–5.
   PubMed Web of Science ®Google Scholar
• Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS. 2003;17(17):2487–2494.
   PubMed Web of Science ®Google Scholar
• Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4(11):1302–1307.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretro-viral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15(1):F1–F9.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Fätkenheuer G, Johnson M, et al. Effect of short-term monotherapy with UK-427,857 on viral load in HIV-infected patients [slides]. Presented at: 43rd Inter- science Conference on Antimicrobial Agents and Chemo-therapy; September 14–17, 2003; Chicago, IL.
   Google Scholar
• Fätkenheuer G, Staszewski S, Plettenburg A, et al. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS. 2009;23(16):2115–2122.
   PubMed Web of Science ®Google Scholar